24 Million Americans Just Lost GLP-1 Coverage — Here's What Actually Happened
NPR reports 12 million lost Zepbound coverage and 12 million lost Wegovy coverage in the past year. CVS Caremark, BCBS Massachusetts, and Harvard Pilgrim all pulled back. Here's the full list — and what you can do right now.
Roughly 24 million Americans were affected by the spring 2026 round of insurance and PBM coverage decisions on GLP-1 weight-loss medications. The number is dramatic, but the situation is more nuanced than the headline number suggests.
Key takeaways
- The change is concentrated in employer plans that previously covered weight-loss-only indications
- Coverage for type 2 diabetes indications was largely unchanged
- Telehealth compounded options have absorbed a significant share of displaced patients
- Out-of-pocket monthly costs in the displaced cohort range from $99 to $400+
What actually changed
Several major employer plans removed weight-loss indication coverage for GLP-1 drugs starting April 2026, citing cost trajectory. Patients on these medications for type 2 diabetes were generally unaffected because the diabetes indication remains covered.
PBMs continue to negotiate on the manufacturer side, and a number of plans introduced step-therapy requirements rather than outright removing coverage.
What displaced patients are doing
The most common pivot has been from brand-name semaglutide or tirzepatide to compounded equivalents through telehealth. Compounded plans typically run $99–$200/month, compared with $1,000+ list-price brand-name prescriptions.
Patients who can wait have also moved to longer plan durations to lock in price stability for the rest of 2026.
Where to start if your plan changed
Compare your current monthly cash price to the cheapest legit compounded options in our review. Several programs offer first-order discounts that bring effective month-one pricing under $99. Check our cheapest-GLP-1 ranking for the current list.